Galectin Therapeutics Inc. Unveils Corporate Presentation on Galectin-Based Therapeutics for Chronic Liver Diseases and Cancer
Reuters
Sep 08
<a href="https://laohu8.com/S/GALT">Galectin Therapeutics Inc</a>. Unveils Corporate Presentation on Galectin-Based <a href="https://laohu8.com/S/LENZ">Therapeutics</a> for Chronic Liver Diseases and Cancer
Galectin Therapeutics Inc. recently unveiled a corporate presentation highlighting their advancements in galectin-based therapeutics. The presentation showcases Belapectin, a novel galectin-3 inhibitor with Fast Track Designation, aimed at treating MASH cirrhosis and portal hypertension. Notable findings include a significant reduction in new varices in cirrhotic patients without varices, with promising results from the NAVIGATE study. Additionally, in oncology, Belapectin is being explored in combination with Keytruda for treating melanoma and head/neck cancer, showing encouraging responses. The company's discovery programs are also focused on developing oral Galectin-3 inhibitors. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief on September 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.